Human multiple myeloma cells express peroxisome proliferator-activated receptor γ and undergo apoptosis upon exposure to PPARγ ligands

This publication has 35 references indexed in Scilit:

• The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
  Blood, 2003
• Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment
  European Journal Of Cancer, 2003
• Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist
  Proceedings of the National Academy of Sciences, 2002
• Emerging roles of PPARS in inflammation and immunity
  Nature Reviews Immunology, 2002
• Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
  Blood, 2002
• Oxidized Alkyl Phospholipids Are Specific, High Affinity Peroxisome Proliferator-activated Receptor γ Ligands and Agonists
  Journal of Biological Chemistry, 2001
• Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
  Blood, 2000
• A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
  Cell, 1995
• 15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
  Cell, 1995
• Biological activities and mechanisms of action of PGJ2 and related compounds: an update
  Prostaglandins, Leukotrienes & Essential Fatty Acids, 1992